Article

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study

2022-08-17

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> WHO has called for research into predictive factors for selecting persons who could be successfully treated with shorter durations of direct acting antiviral (DAA) therapy for Hepatitis C. We evaluated early virological response as a means of shortening treatment and explored host, viral and pharmacokinetic contributors to treatment outcome. <h4>Methods</h4> Duration of sof...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c624dee-43eb-5dd0-ac28-388528fb0532
DOI: 10.1101/2022.08.15.22278752

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot studyDOI 10.1101/2022.08.15.22278752Read

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.Semantic proximity Read

No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.Semantic proximity Read

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.Semantic proximity Read

Hepatitis C treatment: shorter and better?Semantic proximity Read

Response-guided and -unguided treatment of chronic hepatitis C.Semantic proximity Read

Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?Semantic proximity Read

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.Semantic proximity Read

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.Semantic proximity Read

Treatment of hepatitis C in 2011: what can we expect?Semantic proximity Read

Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.Semantic proximity Read

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.Semantic proximity Read